Risk profile and benefits from Gp IIb-IIIa inhibitors among patients with ST-segment elevation...
8
Risk profile and benefits from Gp IIb-IIIa inhibitors among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-regression analysis of randomized trials by Giuseppe De Luca, Eliano Navarese, and Paolo Marino EHJ Volume 30(22):2705-2713 November 14, 2009 Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2009. For permissions please email: [email protected]
-
Upload
shanon-lawson -
Category
Documents
-
view
222 -
download
0
description
Glycoprotein IIb-IIIa inhibitors and mortality benefits at 30 day follow-up, with odds ratios and 95% confidence intervals (CI). Giuseppe De Luca et al. Eur Heart J 2009;30: Published on behalf of the European Society of Cardiology. All rights reserved. © The Author For permissions please
Transcript of Risk profile and benefits from Gp IIb-IIIa inhibitors among patients with ST-segment elevation...
Risk profile and benefits from Gp IIb-IIIa inhibitors among patients with ST-segment elevation myocardial infarction
treated with primary angioplasty: a meta-regression analysis of randomized trials
by Giuseppe De Luca, Eliano Navarese, and Paolo Marino
EHJVolume 30(22):2705-2713
November 14, 2009
Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2009. For permissions please email: [email protected]
Flow diagram of the systematic overview process.
Giuseppe De Luca et al. Eur Heart J 2009;30:2705-2713
Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2009. For permissions please email: [email protected]
Glycoprotein IIb-IIIa inhibitors and mortality benefits at 30 day follow-up, with odds ratios and 95% confidence intervals (CI).
Giuseppe De Luca et al. Eur Heart J 2009;30:2705-2713
Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2009. For permissions please email: [email protected]
Funnel plot of all studies included in the meta-analysis.
Giuseppe De Luca et al. Eur Heart J 2009;30:2705-2713
Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2009. For permissions please email: [email protected]
(A) Weighted random-effects meta-regression analysis regressing the log odds ratio of mortality against the control group mortality rate expressed as odds using the inverse of the variance of the log odds ratio as weight; this graph shows a relationship between risk profile and mortality
benefits from Gp IIb-IIIa inhibitors.
Giuseppe De Luca et al. Eur Heart J 2009;30:2705-2713
Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2009. For permissions please email: [email protected]
Glycoprotein IIb-IIIa inhibitors and benefits in re-infarction at 30 day follow-up, with odds ratios and 95% confidence intervals (CI).
Giuseppe De Luca et al. Eur Heart J 2009;30:2705-2713
Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2009. For permissions please email: [email protected]
(A) Weighted random-effects meta-regression analysis regressing the log odds ratio of re-infarction against the control group re-infarction rate expressed as odds using the inverse of the
variance of the log odds ratio as weight; this graph shows no relationship between risk profile and benefits in re-infarction from Gp IIb-IIIa inhibitors.
Giuseppe De Luca et al. Eur Heart J 2009;30:2705-2713
Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2009. For permissions please email: [email protected]
Glycoprotein IIb-IIIa inhibitors and major bleeding complications at 30 day follow-up, with odds ratios and 95% confidence intervals (CI).
Giuseppe De Luca et al. Eur Heart J 2009;30:2705-2713
Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2009. For permissions please email: [email protected]
